Early 2026 launch of liquid-filled hard capsule capabilities will expand options for partners, accelerating development & commercialization timelines
Zhunan, Taiwan (September 30, 2025) – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a global leader in pharmaceutical manufacturing, has announced the addition of liquid-filled hard capsule (LFC) production capabilities at its Zhunan, Taiwan facility.
This investment significantly expands Bora’s oral solid dose technology portfolio and strengthens its ability to serve partners with high-potency formulations and advanced delivery formats.
Bora plans to have its high-potency LFC manufacturing capabilities available for customers in Q1 of 2026. A new operational area has been designed at the facility to support the expansion, which will address the growing demand for stable delivery of sensitive compounds and complex pharmaceutical ingredients, such as oncology or potent drugs. The Zhunan facility, which is approved by both the USFDA and MHRA, currently supplies drug products to the United States, Taiwan, and throughout Asia, reinforcing its role as a trusted global supply hub.
“This investment reiterates Bora’s commitment to innovation, infrastructure, and long-term growth,” said J.D. Mowery, president of Bora’s CDMO Business. “By adding liquid capsule manufacturing, we are equipping our partners with optimized formulation that reduces delays and accelerates commercialization.”
The global liquid capsule supplements market is projected to reach $9.1 billion by 2033, as LFCs are increasingly favored for their superior absorption rates and ability to deliver complex formulations compared to other oral options.
Bora’s Zhunan site is one of seven cGMP manufacturing sites operating around the world and delivers drug products to more than 100 countries. The company’s commercial on-time, in-full (OTIF) delivery record is unmatched, reinforcing Bora’s role as a genuine partner, supporting clients with secure, consistent supply.
For more information, visit www.boracdmo.com.
About Bora Pharmaceuticals
Bora Pharmaceuticals is a premier international contract development and manufacturing organization (CDMO) specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products. From our world-class sites in North America and Asia, we deliver drug products with unparalleled quality to more than 100 markets around the world. For more information, visit www.boracdmo.com.